Philip F. Hughes, Ph.D.

Pharmacology & Cancer Biology Duke University, Durham, NC 
Drug Discovery
"Philip Hughes"
Mean distance: 8.71


Sign in to add mentor
Slayton A. Evans research assistant 1975-1976 UNC Chapel Hill
 (Undergraduate research)
Jon C. Clardy grad student 1979-1983 Cornell
Timothy Arthur James Haystead research scientist Duke
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Scarneo S, Hughes P, Freeze R, et al. (2022) Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. Acs Chemical Biology
Wang Y, Scarneo SA, Kim SH, et al. (2021) Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain. Pain
Goswami R, Russell VS, Tu JJ, et al. (2021) Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. Iscience. 103412
Osada T, Crosby EJ, Kaneko K, et al. (2021) HSP90-specific nIR probe identifies aggressive prostate cancers: translation from preclinical models to a human phase I study. Molecular Cancer Therapeutics
Wang R, Alvarez DA, Crouch BT, et al. (2021) Understanding the sources of errors in Hsp90 molecular imaging for rapid-on-site breast cancer diagnosis. Biomedical Optics Express. 12: 2299-2311
Dong B, Jaeger AM, Hughes PF, et al. (2020) Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. Science Translational Medicine. 12
Scarneo SA, Yang KW, Roques JR, et al. (2020) TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. Oncotarget. 11: 1961-1970
Kaneko K, Osada T, Morse MA, et al. (2020) Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. Communications Biology. 3: 226
Scarneo SA, Hughes PF, Yang KW, et al. (2019) A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. The Journal of Biological Chemistry
Scarneo SA, Eibschutz LS, Bendele PJ, et al. (2019) Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research & Therapy. 21: 292
See more...